|
| |
Cubist PharmaceuticalsCubist Pharmaceuticals Incorporated is a drug company focused on the discovery, development and commercialization of novel drugs to treat infections. Daptomycin, the Company's in-licensed lead product, is a unique agent with bactericidal activity that addresses the critical need for new antibiotics with potent activity against life threatening infections. Cubist Pharmaceuticals began Phase III clinical trials of intravenous daptomycin for complicated skin and soft tissue infections and also began a Phase II clinical trial for bacteremia in February of 1999. Cubist is also applying its VITA-TM- technology to validate unique targets and to build assays to identify additional novel compounds with a broad spectrum of activity against life-threatening infectious organisms such as methicillin resistant STAPHYLOCOCCUS AUREUS (MRSA) and vancomycin resistant enterococci (VRE).
| Contact Details: |
| 65 Hayden Avenue |
| Lexington |
| MA |
| 02421 |
| United States of America |
| Tel: | (781) 860-8660 |
| Fax: | (781) 861-0566 |
| Email: | |
| WWW: | www.cubist.com/
|
|
Loading...
|
Recent Publications by Cubist Pharmaceuticals: |  |
Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.
This review summarizes the in vitro and animal model data available on... | 15th October, 2009
| Cubist Pharmaceuticals, Inc., Lexington, MA 02421, USA.
| J Antimicrob Chemother. 2009 Oct 12.
DOI Direct Link |
Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.
The decrease in vancomycin treatment efficacy that is accompanying... | 10th October, 2009
| Cubist Pharmaceuticals, Lexington, MA, USA.
| Lancet Infect Dis. 2009 Oct;9(10):617-24.
DOI Direct Link |
Retrospective review of the use of daptomycin for diabetic foot infections.
The increase in antibiotic resistance has led to a search for alternative... | 1st October, 2009
| Cubist Pharmaceuticals, Lexington, Massachusetts, USA.
| J Wound Care. 2009 Sep;18(9):396-400.
|
Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry.
Antibiotic safety is a major determinant in osteomyelitis therapy. Limited... | 1st October, 2009
| Cubist Pharmaceuticals, Lexington, MA 02421, USA.
| J Chemother. 2009 Aug;21(4):414-20.
|
Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
BACKGROUND: Daptomycin is approved for the treatment of skin and... | 25th September, 2009
| Cubist Pharmaceuticals Inc., Lexington, MA 02421, USA.
| Ann Pharmacother. 2009 Jul;43(7):1211-9. Epub 2009 Jul 7.
DOI Direct Link |
→View more Cubist Pharmaceuticals research publications. |
Press Releases on Cubist Pharmaceuticals:
|
 |
| New Effort to Battle Antibiotic Resistance Rallies Researchers Throughout Harvard University |
13th October, 2009 |
Schepens Eye Research Institute |
BOSTON, Oct. 13 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard
|
| Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications |
29th June, 2009 |
aTyr Pharma |
aTyr Pharma Targets for Novel Biotherapeutics Based On Naturally Resected tRNA Synthetases
SAN DIEGO, June 29 /PRNewswire/ -- Pangu BioPharma, a subsidiary of aTyr Pharma in Hong Kong, today
|
| Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018 |
16th June, 2009 |
Decision Resources |
Uptake of Novel Agents from Novexel, Johnson & Johnson and Wyeth Will Drive Growth, According to a New Report from Decision Resources
WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources,
|
| Scripps Research Institute Highlights Groundbreaking Work of aTyr Pharma Scientific Co-Founder |
8th June, 2009 |
aTyr Pharma |
Research Published by Scripps Associate Professor Xiang-Lei Yang Further Validates aTyr Pharma's Discovery Engine for Proprietary Drugs
SAN DIEGO, June 8 /PRNewswire/ -- The June 1st, 2009
|
| Beactica Announces Drug Discovery Agreement With Cubist Pharmaceuticals |
25th May, 2009 |
Beactica AB |
UPPSALA, Sweden, May 25 /PRNewswire/ -- Beactica AB, the Swedish
fragment-based drug discovery company, today announced that it has entered
into an agreement with Cubist Pharmaceuticals, Inc.
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 15 individuals from Cubist Pharmaceuticals using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 451 times since April 2007, the link to the organisation's website has been followed 49 times Recent Search Terms used to find this page: us patent 7 527 807 | . Search for more companies in Lexington Search for more companies in MA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Cubist Pharmaceuticals |
